Daiichi sends in posse to keep Ranbaxy plant in line

Daiichi Sankyo isn't taking chances on Ranbaxy Laboratories' ability to keep turning out FDA-compliant drugs. The Japanese drugmaker, which owns the controlling interest in the Indian company, has dispatched two executives to the Punjab facility to keep a close eye on operations there, The Economic Times says. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.